What disease does Zanubrutinib treat?

Zanubrutinib (Zanubrutinib) is a drug proven to be effective in treating B-cell cancers without causing unduly severe side effects. Patients with certain B-cell malignancies (cancers of white blood cells) may benefit from treatment with Bruton tyrosine kinase (BTK) inhibitors. These drugs block the BTK protein and prevent the cancer from growing and spreading.

Early data from thePhase 3 ALPINE clinical study suggests thatzanubrutinibworks better thanibrutinib, with fewer patients experiencing side effects and dropping out of treatment. Zanubrutinib is currently approved for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy, Waldenströ macroglobulinemia, and adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20 therapy. Zanubrutinib has good efficacy in its approved indications and appears to reduce cardiotoxicity, particularly in atrial fibrillation.

Zabrutinib is a highly selective BTK inhibitor that forms a covalent bond with the cysteine residue in the active site of BTK, thereby inhibiting BTK activity. The representative drug of the second generation BTK inhibitorsZanbrutinibstill inhibitsEGFR, HER2, ITK, JAK3, TEC, BMX and BLK, although its off-target effects are significantly reduced compared with the first generation BTK inhibitors.

The original drug of zanubrutinib has been launched in China and has been included in the medical insurance. The price of 80mg*64 capsules per box may be around 6,000 yuan. The original drug of zanubrutinib marketed overseas is relatively expensive. There are currently no generic drugs of zanubrutinib on the market.